Drug Database
LA

Lactobacillus vaccine (Ginatren vaccine / SolcoTrichovac / Gynatren vaccine)

✓ Approved

Takeda · 细胞治疗 · 细胞治疗

什么是 Lactobacillus vaccine?

Lactobacillus vaccine 是一种细胞治疗,由Takeda研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection、Oral (PO)。

药物档案

商品名Ginatren vaccine, SolcoTrichovac, Gynatren vaccine
公司Takeda
药物类别细胞治疗, 疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection, Oral (PO)
状态Approved

治疗适应症

Lactobacillus vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsGynaecological chlamydia infection✓ Approved

相关研究文献

PubMedIDCases2026-11-17

Lactobacillus fermentum bacteremia associated with a multiloculated pyogenic liver abscess in a patient with diabetic ketoacidosis: A case report.

Anto Anandu Mathews AM, Mandalapu Navya N, Nallapareddy RahulReddy R, Zeana Cosmina C et al.

Lactobacillus species are Gram-positive commensal organisms found in the human body. Although generally considered low-virulence organisms and most often dismissed as contaminants, Lactobacillus species isolated from blood cultures have increasingly been recognized as causes of invasive infections in patients with severe comorbidities. Pyogenic liver abscess associated with Lactobacillus is exceedingly rare. A 51-year-old woman with poorly controlled diabetes mellitus presented with fever, abdominal pain, acute encephalopathy, and generalized weakness. She was found to have severe diabetic ketoacidosis. Abdominal imaging revealed a large multiloculated liver abscess that was drained. Gram stain of the aspirate fluid revealed gram-positive rods, and two blood culture sets obtained 4 h apart grew Lactobacillus fermentum. The patient was treated with appropriate antimicrobial therapy for 6 weeks in addition to source control with percutaneous drainage, resulting in marked clinical improvement. This case adds to the small body of literature describing Lactobacillus-associated pyogenic liver abscess. Isolation of Lactobacillus species from sterile sites should prompt careful clinical review rather than automatic dismissal as contamination.

PMID 43041647
阅读全文 →
PubMedBMC microbiology2026-11-17

Genomic characterization of a novel Lactobacillus species from pangolin feces: phylogenomic placement and unique functional gene repertoire.

Yu Sijia S, Hong Peihang P, Chou Shyun S, Liang Tsui-Fang TF et al.

The genus Lactobacillus represents a phylogenetically and ecologically diverse group of lactic acid bacteria intimately linked to host gastrointestinal homeostasis and widely regarded as prime probiotic candidates. Pangolin conservation is severely challenged by high mortality rates driven by digestive tract diseases, yet their native gut microbial ecology, particularly the functional roles of resident lactobacilli, remains largely unexplored. In this study, a novel Lactobacillus strain, designated M44, was isolated from the feces of a wild Formosan pangolin, and its complete genome was resolved via whole-genome sequencing. Genome-wide taxonomic metrics (ANI, AAI, and dDDH) fell substantially below the established thresholds for known species. Phylogenomic reconstruction based on single-copy orthologs confirmed that strain M44 forms a distinct, novel evolutionary lineage clustering adjacent to L. psittaci, L. jensenii, and L. mulieris. Comparative genomic analysis revealed that while M44 shares a core of 936 orthogroups with these phylogenetically related peers, it maintains a unique repertoire of 207 strain-specific orthogroups. Multi-pipeline functional mining identified a robust gene cluster for exopolysaccharide biosynthesis, alongside an array of surface-anchored adhesins that support its strong mucosal colonization potential. From an antimicrobial defense perspective, genome mining identified no canonical bacteriocin gene clusters, while genes associated with organic acid and hydrogen peroxide biosynthesis were present. Metabolic pathway reconstruction identified genomic capacity for exogenous carbohydrate and peptide utilization, including catabolic pathways for trehalose and N-acetylglucosamine, as well as a comprehensive oligopeptide permease system and an extensive intracellular peptidase repertoire. Genomic safety screening confirmed the complete absence of acquired antimicrobial resistance genes and intact mobile genetic elements, reinforced by an active Type I-E CRISPR-Cas adaptive immune system. These genomic insights establish strain M44 as a novel Lactobacillus species with a functional architecture encompassing broad exogenous carbohydrate and peptide utilization capacity, enhanced intestinal adherence capabilities, and organic acid-mediated antimicrobial defense. The demonstration of a favorable genomic safety profile, combined with prior in vitro phenotypic screening, positions Lactobacillus sp. M44 as a scientifically compelling subject for wildlife microbiome exploration and a candidate worthy of further investigation for potential application in captive pangolin management.

PMID 43040481
阅读全文 →
PubMedBMC public health2026-11-17

Post-introduction evaluation of COVID-19 vaccine deployment in Ghana: lessons learnt to inform future new vaccine introductions and strengthen public health readiness, 2023.

Amponsa-Achiano Kwame K, Shen Angela K AK, Baiden Laryea Eunice E, Carlton Julie Garon JG et al.

On March 2nd, 2021, Ghana, the first country to receive vaccines from the COVAX facility, began its COVID-19 vaccination using a complex multi-phased approach, to reach target populations. We evaluated the vaccine deployment to document best practices challenges and lessons for future new vaccine introductions and public health emergency readiness. We conducted a mixed methods post-introduction evaluation, purposively sampling 36 facilities from 12 districts in six regions. Adapting the World Health Organization's COVID-19 Post-Introduction Evaluation tool, we conducted a cross-sectional survey using a structured questionnaire, reviewed programme records, observed practices, and interviewed purposively selected health workers, immunization managers and partners who supported vaccine deployment. We performed summary descriptive statistics on quantitative data, thematic analysis on qualitative data, and triangulated the results. As of March 2023, more than 70% of the target population (15 years and older) had received at least one dose, while more than 50% had completed the primary series. Vaccine deployment was built on the existing immunisation programme and functional coordinating bodies. Cold chain capacity was revamped with ultra-low-temperature freezers, while 33.3% of surveyed districts adjusted waste disposal systems to accommodate COVID-19 vaccine introduction. Door-to-door delivery and demand generation through varied risk communication and community engagement strategies improved vaccine access. Electronic data platforms were established, surge capacity improved, and healthcare and community workers were trained. Initial unpredictable vaccine supplies limited vaccination efforts. Changing vaccine information affected health workers' ability to engage communities with up-to-date guidance. While vaccine safety monitoring systems were in place, reporting knowledge varied among health workers, and 36% of surveyed facilities had ever documented and reported COVID-19 vaccine-related adverse events following immunisation. Challenges with electronic data systems limited timely access to and use of granular service-delivery data for decision-making. Ghana leveraged existing immunisation and emergency-response systems to make substantial progress in COVID-19 vaccine deployment. Coordination, cold chain expansion, flexible service delivery, demand generation and workforce mobilisation supported implementation. Irregular vaccine supply, data system challenges, variable adverse event reporting, waste management pressure and misinformation challenged deployment. These findings provide lessons for adult immunisation, life-course vaccination and future public health emergency readiness.

PMID 43040294
阅读全文 →
PubMedACI open2026-11-17

Enhancing Human Papillomavirus Vaccine Communication with Mobile Health: Usability Insights from Caregivers and Health Care Providers.

Reisher Elizabeth E, Anyanwu Evangel E, Figliomeni Jonathan J, Honcoop Adrien A et al.

Despite the effectiveness of the human papillomavirus (HPV) vaccine in preventing cancer, uptake remains suboptimal, especially among rural and underserved populations. Digital communication tools such as mobile health (mHealth) applications have the potential to improve access to accurate vaccine information and support shared decision-making. This study aimed to assess the usability, acceptability, and perceived usefulness of a newly developed mHealth app for HPV vaccine communication in comparison to the Centers for Disease Control and Prevention's (CDC) HPV vaccine Web site. Using a mixed-methods design and guided by the Health Belief Model and the mHealth Agile Development and Evaluation Lifecycle, caregivers, and health care providers were randomized to explore both the CDC Web site and the mHealth app in alternating order. Participants were asked to complete a session answering HPV vaccine questions with each tool and completed the mHealth App Usability Questionnaire, Propensity to Trust, and NASA Task Load Index (NASA-TLX) after each session. Qualitative questions were asked after each session to capture additional feedback on items such as navigation and readability. Transcripts were analyzed using inductive thematic analysis. Quantitative results showed no difference between the tools in terms of being easy to use, requiring similar amounts of effort, and trust in the tool. Qualitative themes revealed that participants appreciated the app's streamlined navigation, tailored content, and readability. In contrast, the CDC Web site was seen as credible but often difficult to navigate, especially when searching for nuanced or specific vaccine information. Tailored mHealth tools developed with user-centered design principles may better meet the informational and usability needs of caregivers and health care providers compared with existing web-based resources. These findings support further development and integration of mHealth tools into vaccine communication strategies to enhance HPV vaccine communication.

PMID 43042227
阅读全文 →
PubMedInfection and immunity2026-11-17

Co-administration of DTaP with COVID-19 mRNA vaccine in mice alters immune responses and induces increased protection from Bordetella pertussis challenge.

Rader Nathaniel N, Boehm Dylan T DT, Bitzer Graham J GJ, Chapman Joshua J et al.

During the COVID-19 pandemic, children received COVID-19 mRNA vaccines alongside other regularly scheduled immunizations, such as the acellular Bordetella pertussis vaccine DTaP. It is known that mRNA vaccines are pro-inflammatory in nature, leading to protective immunity against SARS-CoV-2 infection. The goal of this study was to investigate the potential adjuvanticity of co-administration of a COVID-19 mRNA vaccine alongside DTaP. Mice were immunized with DTaP alone or with a co-administration of DTaP plus COVID-19 mRNA vaccine. To understand the impact of co-administration, we evaluated protection against B. pertussis aerosol challenge in mice and potential correlates of protection, including cytokine responses to vaccination, antibody responses, and single-cell transcriptomic analysis of the draining lymph node. Three decreasing doses of each vaccine were used to simulate waning immunity. Overall, compared to mice immunized with DTaP, co-administration of DTaP + COVID-19 mRNA vaccines elicited higher pro-inflammatory cytokine responses, higher IgG2b antibody responses, and mice were afforded increased protection against aerosol challenge of B. pertussis. Single-cell transcriptomics studies on the lymph node of vaccinated mice at 1 day post-boost further characterized how co-administration of COVID-19 mRNA vaccine alongside DTaP vaccine shapes immunity. Single-cell transcriptomics revealed that co-administration of DTaP and COVID-19 mRNA vaccine generated populations of B and T cells with upregulated expression of interferon-stimulated genes, which were absent when vaccinating with DTaP alone. Altogether, these data suggest that administering DTaP alongside COVID-19 mRNA vaccine alters immune responses and provides increased protection from an aerosol challenge of B. pertussis compared to DTaP alone in mice.

PMID 43043313
阅读全文 →
PubMedFrontiers in veterinary science2026-11-17

Ginsenoside Rg1 as an adjuvant enhances immunity in chickens immunized with the H9N2 avian influenza inactivated vaccine.

Zhang Pengju P, Wang Hongtao H, Li Mengman M, Lyu Xuefeng X et al.

To investigate the potential use of Ginsenoside Rg1 as an adjuvant for the H9N2 avian influenza vaccine, the study examined Rg1's immunomodulatory effects on an inactivated H9N2 vaccine. A total of 150 one-day-old non-immunized Arbor Acres (AA) chickens were randomly assigned to three groups (n = 50 each): one receiving the H9N2 inactivated vaccine, another receiving Rg1 alongside the vaccine, and a control group treated with PBS. Each group underwent three immunization sessions spaced 2 weeks apart. Serum samples were taken to measure IgG antibody levels and hemagglutination inhibition (HI) titers. Lymphocyte proliferation was assessed using cell counting kits-8 and flow cytometry. The levels of serum cytokines, including Interferon-γ (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-4, and IL-6, were quantified via ELISA. Fourteen days post-final immunization, the chickens were challenged with the H9N2 strain, and viral titers in the lungs and kidneys were measured. Findings indicated that the group receiving Rg1 with the vaccine exhibited a notable increase in specific IgG and HI titers. Furthermore, this group showed enhanced T cell proliferation and elevated cytokine production, thereby bolstering cellular immunity. Importantly, the immune protection results revealed that the combination of Rg1 and the vaccine significantly improved the chickens' protection against viral strains, leading to a marked reduction in viral shedding. These findings imply that Rg1 may enhance the immune response and protective efficacy of the H9N2 inactivated vaccine, positioning it as a promising new adjuvant for H9N2 vaccination.

PMID 43041234
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Lactobacillus vaccine